Impax Laboratories, Inc. (NASDAQ:IPXL) posted its earnings results on Thursday. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03, Bloomberg Earnings reports. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm had revenue of $206.40 million for the quarter, compared to analysts’ expectations of $208.38 million. During the same period in the previous year, the firm earned $0.37 earnings per share. The business’s revenue was down 9.4% compared to the same quarter last year. Impax Laboratories updated its FY17 guidance to $0.60-0.65 EPS.
Shares of Impax Laboratories (NASDAQ IPXL) opened at $18.30 on Friday. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $25.70. The company has a market capitalization of $1,450.00, a price-to-earnings ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.99. The company has a quick ratio of 1.19, a current ratio of 1.81 and a debt-to-equity ratio of 1.59.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2017/11/11/impax-laboratories-inc-ipxl-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
Several equities research analysts recently weighed in on IPXL shares. Royal Bank Of Canada set a $15.00 price target on Impax Laboratories and gave the stock a “hold” rating in a research note on Sunday, July 16th. Zacks Investment Research cut Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Deutsche Bank AG set a $21.00 price target on Impax Laboratories and gave the stock a “buy” rating in a research note on Monday, July 17th. Piper Jaffray Companies raised Impax Laboratories from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $9.00 to $16.00 in a research note on Tuesday, July 18th. Finally, Canaccord Genuity started coverage on Impax Laboratories in a research note on Monday, July 31st. They issued a “hold” rating and a $19.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.50.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.